Management of MCAS with SIBO

Introduction to Treatment

The American College of Allergy, Asthma, and Immunology recommends oral cromolyn sodium as the next treatment priority for gastrointestinal symptoms in patients with MCAS and SIBO who cannot tolerate H2 blockers, combined with continued H1 antihistamine therapy and treatment of the underlying SIBO 1, 2

Oral cromolyn sodium is specifically effective for gastrointestinal symptoms including bloating, diarrhea, and abdominal cramps in MCAS patients, starting at low doses (typically 100mg four times daily) and gradually increasing to 200mg four times daily as tolerated 1, 2
Continue or optimize H1 antihistamine therapy with second-generation agents like fexofenadine or cetirizine at 2-4 times standard FDA-approved doses for dermatologic symptoms, tachycardia, and abdominal discomfort 1, 3
Cyproheptadine is specifically recommended for diarrhea and nausea in MCAS patients and functions as both an H1 blocker and serotonin receptor antagonist 2, 3
Ketotifen, a sedating H1 antihistamine, treats dermatologic, gastrointestinal, and neuropsychiatric symptoms in MCAS 3, 4

Treat the underlying SIBO with broad-spectrum antibiotics for 2 weeks (rifaximin, ciprofloxacin, or amoxicillin) 5
Probiotics may help decrease gastrointestinal symptoms in patients with diarrhea and flatulence 5

Leukotriene modifiers (montelukast, zafirlukast, or zileuton) work best in conjunction with H1 antihistamines and may help with both dermatologic and gastrointestinal symptoms 1, 2, 3
Aspirin may reduce flushing and hypotensive episodes associated with prostaglandin D2 secretion, but must be introduced in a controlled clinical setting due to risk of triggering mast cell degranulation 1, 2, 3

Ensure the patient has an epinephrine autoinjector given the history of severe systemic symptoms and potential for anaphylaxis 1, 2, 3
Introduce new medications cautiously in a controlled setting with emergency equipment available, as MCAS patients may experience paradoxical reactions 2, 4
Avoid first-generation sedating antihistamines in elderly patients due to risk of cognitive decline and impaired driving ability 1, 3, 4

Increase water intake significantly to maintain hydration given the severe diarrhea 5
Reduce dietary lactose, fat, and fiber intake during acute diarrhea episodes 5
Eat slowly and avoid gas-producing foods (such as cruciferous vegetables) and chewing gum to reduce flatulence 5
Separate liquids from solids by at least 30 minutes to help manage dumping-like symptoms 5

Short-term corticosteroid burst (0.5 mg/kg/day oral prednisone) with slow taper over 1-3 months may be necessary for refractory symptoms 1
Omalizumab (anti-IgE therapy) has shown efficacy in preventing anaphylactic episodes in MCAS patients resistant to mediator-targeted therapies 1, 2

The American Academy of Allergy, Asthma, and Immunology recommends H1 and H2 antihistamines as preventive therapy for patients with MCAS and POTS, as these medications function as prophylactic agents to prevent mast cell mediator effects rather than simply treating acute flares 6
Antihistamines work by attenuating the clinical response to mast cell activation by reducing mediator production or blocking mediator action with ongoing medical therapy 6

Second-generation H1 antihistamines are preferred for long-term use and can be increased to 2-4 times the standard FDA-approved dose for optimal symptom control 6
The American Geriatrics Society recommends avoiding first-generation sedating H1 antihistamines for chronic use, particularly in elderly patients, due to risk of drowsiness, impaired driving ability, and cognitive decline 6, 7

H2 antihistamines serve as first-line therapy for gastrointestinal symptoms and may help H1 antihistamines attenuate cardiovascular symptoms when used in combination 6
Combined H1 and H2 therapy demonstrates greater efficacy than either agent alone for controlling severe symptoms, particularly gastrointestinal manifestations 7
Famotidine or ranitidine are the recommended H2 blockers for continuous use 7

If H1 and H2 antihistamines alone provide inadequate control, the American Academy of Allergy, Asthma, and Immunology suggests adding oral cromolyn sodium for gastrointestinal symptoms, with potential benefit extending to neuropsychiatric manifestations 6
The American Academy of Allergy, Asthma, and Immunology recommends considering leukotriene modifiers (montelukast) in conjunction with antihistamines for refractory symptoms 6
Ensure epinephrine autoinjector availability given the risk of severe systemic reactions and potential anaphylaxis 6